Chronic pain: cannabis research overview
A useful treatment should make a meaningful difference to daily life: movement, sleep or participation in valued activities. A lower pain score alone does not answer every question. Before an appointment, record previous treatments, unwanted effects and the goals that remain unmet. The decision concerns a specific preparation rather than cannabis as one uniform product.
Research profile, not a treatment recommendation
Evidence
The updated review concerns chronic nerve pain. Its uncertain findings justify neither a general promise of benefit nor the claim that nobody can benefit. An older statistic from the 2018 version does not automatically represent current evidence. Back pain, inflammatory pain and neuropathic pain should not be treated as interchangeable research populations. For each study, check who participated, what was compared and whether the measured difference matters in everyday life.
Mechanism of action
A mechanism described in a laboratory is not evidence of benefit in humans. Clinical outcomes for the specific condition and medicine matter. Receptor or terpene models do not predict individual treatment success.
Understanding cannabinoid and terpene profiles
The diagnosis alone cannot establish a universally recommended THC:CBD ratio or terpene profile. Pharmaceutical quality, the studied use and personal risks matter. A strain name or aroma profile cannot replace that assessment.
Individual dosing and monitoring
This reference provides no starting dose or escalation schedule. If treatment is considered, the preparation, dose, adjustments and monitoring must be individualised. Different products are not directly interchangeable; drops and sprays are not universal dose units.
Routes of administration
The route of administration is part of choosing a specific medicine. Results for one standardised preparation do not automatically establish the effects of another form. Discuss changes with the treating clinician.
Side effects
Discuss drowsiness, falls, mental health symptoms and interactions with your full medication list. Agree how benefits and burdens will be assessed and when treatment will be reconsidered. A THC:CBD ratio or dose found online is not an individual treatment plan. Do not independently replace or stop other pain medicines.
Interactions & cautions
Have the complete medication list checked, including non-prescription products. CBD can also cause interactions. Pregnancy, breastfeeding, liver disease and previous mental health difficulties may matter; the specific medicine’s prescribing information is decisive.
Prescription & insurance (Switzerland)
Since August 2022, medical prescribing of cannabis medicines no longer requires an exceptional FOPH permit. This does not establish authorisation for every condition or automatic reimbursement. The preparation, indication and applicable reimbursement rules need separate assessment.
Driving fitness
If a person can demonstrate that THC comes from medication prescribed by a doctor, its presence alone does not establish unfitness to drive (Article 2(2ter) of the Swiss Traffic Rules Ordinance). Actual driving ability remains decisive. A prescription is therefore not blanket permission to drive. Discuss possible effects on attention and reactions with your treating clinician. Do not drive while impaired, and take particular care when starting or changing treatment. Safety-sensitive tasks at work also need an individual assessment.
FAQ
What can be said about effectiveness?
Cannabis is not an established treatment for every type of chronic pain. The 2026 Cochrane review rates evidence for neuropathic pain as low to very low certainty. Whether a particular medicine is appropriate requires clinical assessment of the diagnosis, previous treatments, everyday limitations and risks.
Does a prescription guarantee reimbursement?
No. Prescribing, medicine authorisation and reimbursement are separate questions. Clarify which rules apply to the preparation and indication, including whether prior reimbursement approval is needed.
Is there a universally recommended product profile?
The diagnosis alone cannot establish a universally recommended THC:CBD ratio or terpene profile. Pharmaceutical quality, the studied use and personal risks matter. A strain name or aroma profile cannot replace that assessment.
Does a prescription automatically allow driving?
A prescription alone cannot answer that question. Where medically prescribed use is demonstrated, detecting THC does not by itself establish unfitness to drive. Driving while impaired remains prohibited. Discuss your individual circumstances with your treating clinician.